Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) just unveiled an update.
Hangzhou Tigermed Consulting Co., Ltd. announced a share transfer agreement where its subsidiary, Jiaxing Xinge Medical Consulting Co., Ltd., will sell the entire issued share capital of Teddy Clinical Research Laboratory (Shanghai) Ltd. to Frontage Laboratories (Shanghai) Co., Ltd., a subsidiary of Frontage Holdings Corporation, for RMB270,000,000. This intra-group transaction is expected to optimize resource allocation, enhance operational efficiency, and promote synergies within the Group by consolidating the Target Group’s operations under the Frontage Group, thereby improving cost efficiency and operational focus.
The most recent analyst rating on (HK:3347) stock is a Hold with a HK$50.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a leading China-based provider of comprehensive biopharmaceutical research and development services. The company is primarily engaged in offering one-stop and professional clinical research services for innovative drugs, medical devices, and biotechnology-related products to both domestic and international enterprises.
Average Trading Volume: 3,701,141
Technical Sentiment Signal: Buy
Current Market Cap: HK$49.58B
For a thorough assessment of 3347 stock, go to TipRanks’ Stock Analysis page.